RS54987B1 - Lečenje osteoporoze - Google Patents

Lečenje osteoporoze

Info

Publication number
RS54987B1
RS54987B1 RS20160550A RSP20160550A RS54987B1 RS 54987 B1 RS54987 B1 RS 54987B1 RS 20160550 A RS20160550 A RS 20160550A RS P20160550 A RSP20160550 A RS P20160550A RS 54987 B1 RS54987 B1 RS 54987B1
Authority
RS
Serbia
Prior art keywords
osteoporosis
treatment
Prior art date
Application number
RS20160550A
Other languages
English (en)
Inventor
Stephen Hodges
Robin Soper
Original Assignee
Haomamedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haomamedica Ltd filed Critical Haomamedica Ltd
Publication of RS54987B1 publication Critical patent/RS54987B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
RS20160550A 2009-12-23 2010-12-22 Lečenje osteoporoze RS54987B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0922513.7A GB2476644B (en) 2009-12-23 2009-12-23 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
EP10801459.8A EP2536398B1 (en) 2009-12-23 2010-12-22 Treatment of osteoporosis
PCT/GB2010/052195 WO2011077159A1 (en) 2009-12-23 2010-12-22 Treatment of osteoporosis

Publications (1)

Publication Number Publication Date
RS54987B1 true RS54987B1 (sr) 2016-11-30

Family

ID=41716867

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160550A RS54987B1 (sr) 2009-12-23 2010-12-22 Lečenje osteoporoze

Country Status (22)

Country Link
US (2) US8895624B2 (sr)
EP (1) EP2536398B1 (sr)
JP (1) JP5922033B2 (sr)
KR (1) KR101805940B1 (sr)
CN (1) CN103002886B (sr)
AU (1) AU2010334566B2 (sr)
BR (1) BR112012017773B1 (sr)
CA (1) CA2785553C (sr)
CY (1) CY1117805T1 (sr)
DK (1) DK2536398T3 (sr)
GB (1) GB2476644B (sr)
HK (1) HK1178057A1 (sr)
HR (1) HRP20160832T1 (sr)
HU (1) HUE028400T2 (sr)
IL (1) IL220620A (sr)
PL (1) PL2536398T3 (sr)
PT (1) PT2536398T (sr)
RS (1) RS54987B1 (sr)
RU (1) RU2562976C2 (sr)
SI (1) SI2536398T1 (sr)
SM (1) SMT201600224B (sr)
WO (1) WO2011077159A1 (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2476644B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
GB2476643B (en) * 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640651A (en) * 1979-09-12 1981-04-16 Takeda Chem Ind Ltd Quinone compound and its preparation
JPS55153739A (en) 1979-05-18 1980-11-29 Takeda Chem Ind Ltd Quinone compound and its preparation
GB8310141D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Naphthoquinone derivatives
MX9203040A (es) 1984-08-01 1992-07-31 Takeda Chemical Industries Ltd Derivados de quinona y composicion farmaceutica que los contiene.
WO1986000887A1 (en) 1984-08-01 1986-02-13 Takeda Chemical Industries, Ltd. Quinone derivatives, process for their preparation, and medicinal composition containing the same
US4734282A (en) 1986-04-23 1988-03-29 Duke University Rodenticidal compositions containing 1,4-naphthoquinone derivatives
JP2756941B2 (ja) 1996-01-26 1998-05-25 東國製薬株式会社 2−クロロ−3−アリールアミノ−1,4−ナフトキノン誘導体の血小板凝集抑制剤としての用途
GB9613309D0 (en) * 1996-06-25 1996-08-28 Univ Sheffield Quinone bacterial inhibitors
US5849793A (en) 1997-08-15 1998-12-15 The Picower Institute For Medical Research HIV matrix protein tyrosine position 29 pocket binders
ATE333272T1 (de) * 1999-10-19 2006-08-15 Meiji Dairies Corp Verwendung von nahrungsmittel in der prophylaxe und behandlung von stoffwechselbedingten knochenerkrankungen
EP1414387A2 (en) * 2001-08-03 2004-05-06 Vitak B.V. Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
US20050222258A1 (en) * 2003-02-21 2005-10-06 Feixin Wang Pharmaceuticals comprising shikonins as active constituent
JPWO2006126541A1 (ja) * 2005-05-27 2008-12-25 塩野義製薬株式会社 ビタミンk類含有医薬組成物
PL2046312T3 (pl) * 2006-07-14 2021-02-08 Kaydence Pharma As Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2
GB2476643B (en) * 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
GB2476644B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis

Also Published As

Publication number Publication date
CA2785553C (en) 2017-09-05
CN103002886A (zh) 2013-03-27
BR112012017773A2 (pt) 2016-04-19
CY1117805T1 (el) 2017-05-17
HUE028400T2 (en) 2016-12-28
PL2536398T3 (pl) 2016-12-30
IL220620A (en) 2016-02-29
KR101805940B1 (ko) 2017-12-06
EP2536398A1 (en) 2012-12-26
HK1178057A1 (zh) 2013-09-06
US20150141339A1 (en) 2015-05-21
CA2785553A1 (en) 2011-06-30
DK2536398T3 (en) 2016-08-01
GB0922513D0 (en) 2010-02-10
US8895624B2 (en) 2014-11-25
US20130030050A1 (en) 2013-01-31
BR112012017773B1 (pt) 2021-10-26
AU2010334566A1 (en) 2012-07-19
JP2013515712A (ja) 2013-05-09
RU2562976C2 (ru) 2015-09-10
AU2010334566B2 (en) 2016-12-01
EP2536398B1 (en) 2016-04-13
WO2011077159A1 (en) 2011-06-30
PT2536398T (pt) 2016-07-15
SI2536398T1 (sl) 2016-10-28
KR20120123667A (ko) 2012-11-09
GB2476644A (en) 2011-07-06
SMT201600224B (it) 2016-08-31
JP5922033B2 (ja) 2016-05-24
HRP20160832T1 (hr) 2016-09-23
RU2012130936A (ru) 2014-01-27
US9622989B2 (en) 2017-04-18
GB2476644B (en) 2012-11-14
CN103002886B (zh) 2016-10-26

Similar Documents

Publication Publication Date Title
IL218575A0 (en) Treatment of cancer
IL217824A0 (en) Treatment of of macrophage-related disorders
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
GB0915515D0 (en) Treatment of vasculoproliferative conditions
IL206491A0 (en) Treatment of produce
EP2632354A4 (en) REDUCED EXTRACTION OF BONE CEMENT
GB0901456D0 (en) Treatment of psoriasis
GB0900599D0 (en) Treatment
ZA201202213B (en) Treatment of minerals
ZA201107948B (en) Treatment of water
GB201018622D0 (en) Treatment of liquids
GB201013898D0 (en) Well treatment
GB0914839D0 (en) Treatment of oil
EP2413698A4 (en) PROCESS FOR TREATING OSTEOPOROSIS
SG10201408187XA (en) Treatment of Bone Fracture
GB0908101D0 (en) Treatment of stress
IL200753A0 (en) Treatment of psoriasis
HK1178057A1 (zh) 骨質疏鬆的治療
GB201001521D0 (en) Treatment
GB0916686D0 (en) Treatment of cancer
GB0913968D0 (en) Treatment
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
GB201007071D0 (en) Treatment of cartilage resorption
EP2440238A4 (en) Methods of Treatment
GB0918382D0 (en) Osteoporosis treatment